Trial Profile
Phase 3, multicenter, multi-national, randomized, partial double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Alfimeprase (Primary)
- Indications Catheter thrombosis; Peripheral arterial occlusive disorders
- Focus Registrational; Therapeutic Use
- Acronyms NAPA-2
- Sponsors Nuvelo
- 01 Mar 2010 Primary endpoint results published in the Journal of Vascular Surgery
- 12 May 2009 ARCA-biopharma-Inc added as trial sponsor and trial affiliate, lead trial centre aaded as reported by ClinicalTrials.gov.
- 18 Nov 2005 New trial record.